The interim phase 2 data of vesleteplirsen (which consists of a PMO conjugated to the R6Gly peptide) trial revealed mean 11% of exon skipping and 5.7% of dystrophin expression after 7 monthly doses (Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51|Sarepta Therapeutics, Inc. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-positive-data-part-b-momentum). The gene discussed is DMD; the disease is Duchenne muscular dystrophy.